Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Evacetrapib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP known ✓ | P11597 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Evacetrapib SCHEMBL20780398 | 1.00 | CETP (1.00) | CETP | |
| Evacetrapib SCHEMBL108367 | 1.00 | CETP (1.00) | CETP | |
| Evacetrapib SCHEMBL20308644 | 1.00 | CETP (1.00) | CETP | |
| Evacetrapib SCHEMBL141340 | 1.00 | CETP (1.00) | CETP | |
| Evacetrapib SCHEMBL145131 | 0.99 | CETP (0.99) | CETP | |
| Evacetrapib SCHEMBL141258 | 0.99 | CETP (0.99) | CETP | |
| Evacetrapib SCHEMBL141256 | 0.99 | CETP (0.99) | CETP | |
| Evacetrapib SCHEMBL139419 | 0.99 | CETP (0.99) | CETP | |
| Evacetrapib SCHEMBL145129 | 0.99 | CETP (0.99) | CETP | |
| Evacetrapib SCHEMBL139421 | 0.99 | CETP (0.99) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 370 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | claimed |
| US-20240148913-A1 | LIPOSOMAL NANOCARRIER DELIVERY SYSTEM FOR TARGETING ACTIVE CD44 MOLECULE,PREPARATION METHOD THEREFOR, AND USES THEREOF | BEIJING INNO MEDICINE CO., LTD. (CN) | 2024-05-09 | — | — | US | claimed |
| CN-114886900-B | Application of Evacerapib in preparation of antibacterial drugs | 暨南大学 | 2024-02-09 | — | — | CN | claimed |
| US-20230414579-A1 | PHARMACEUTICALS FOR COVID19 TREATMENT | NANTCELL, INC. | 2023-12-28 | — | — | US | claimed |
| CN-117214343-A | Method for determining residual solvent in carboxylic acid compound containing nitrogen heterocycle | 重庆希韦医药科技有限公司 | 2023-12-12 | — | — | CN | claimed |
| EP-4228644-A1 | PHARMACEUTICALS FOR COVID19 TREATMENT | Nantcell, Inc. (US) | 2023-08-23 | — | — | EP | claimed |
| CN-112206326-B | Amino acid self-assembled nanocarrier delivery system for targeted activation of CD44 molecules, preparation method and application thereof | 北京茵诺医药科技有限公司 | 2023-06-02 | — | — | CN | claimed |
| CN-112274651-B | Polydopamine nano-carrier delivery system for targeted activation of CD44 molecules, preparation method and application thereof | 北京茵诺医药科技有限公司 | 2023-06-02 | — | — | CN | claimed |
| CN-112274646-B | Amphiphilic protein-macromolecule conjugate delivery system for targeted activation of CD44 molecules, preparation method and application thereof | 北京茵诺医药科技有限公司 | 2023-06-02 | — | — | CN | claimed |
| WO-2022081406-A1 | PHARMACEUTICALS FOR COVID19 TREATMENT | IMMUNITYBIO, INC. (US) | 2022-04-21 | — | — | WO | claimed |
| US-20170336420-A1 | METHODS AND KITS FOR TREATING CARDIOVASCULAR DISEASES | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2017-11-23 | — | — | US | claimed |
| EP-3215180-A1 | METHODS AND KITS FOR TREATING CARDIOVASCULAR DISEASES | Rappaport Family Institute for Research in the Medical Sciences (IL) | 2017-09-13 | — | — | EP | claimed |
| WO-2016071907-A1 | METHODS AND KITS FOR TREATING CARDIOVASCULAR DISEASES | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2016-05-12 | — | — | WO | claimed |
| EP-2448933-B1 | TRANS-4-[[(5S)-5-[[[3,5-BIS(TRIFLUOROMETHYL)PHENYL]METHYL](2-METHYL-2H-TETRAZOL-5-YL)AMINO]-2,3,4,5-TETRAHYDRO-7,9-DIMETHYL-1H-1-BENZAZEPIN-1-YL]METHYL]-CYCLOHEXANECARBOXYLIC ACID | LILLY CO ELI (US) | 2013-08-28 | — | — | EP | claimed |
| US-8299060-B2 | Trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid | ELI LILLY AND COMPANY (US) | 2012-10-30 | — | — | US | claimed |
| EP-2448933-A1 | TRANS-4-[[(5S)-5-[[[3,5-BIS(TRIFLUOROMETHYL)PHENYL]METHYL](2-METHYL-2H-TETRAZOL-5-YL)AMINO]-2,3,4,5-TETRAHYDRO-7,9-DIMETHYL-1H-1-BENZAZEPIN-1-YL]METHYL]-CYCLOHEXANECARBOXYLIC ACID | Eli Lilly and Company (US) | 2012-05-09 | — | — | EP | claimed |
| US-20120058990-A1 | Trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid | ELI LILLY AND COMPANY (US) | 2012-03-08 | — | — | US | claimed |
| WO-2011002696-A1 | TRANS-4-[[(5S)-5-[[[3,5-BIS(TRIFLUOROMETHYL)PHENYL]METHYL] (2-METHYL-2H-TETRAZOL-5-YL)AMINO]-2,3,4,5-TETRAHYDRO-7,9-DIMETHYL-1H-1-BENZAZEPIN-1-YL]METHYL]-CYCLOHEXANECARBOXYLIC ACID | ELI LILLY AND COMPANY (US) | 2011-01-06 | — | — | WO | claimed |
| US-20100331309-A1 | Trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid | ELI LILLY AND COMPANY (US) | 2010-12-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058990-A1 | Trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NT5C, HTR5A | CETP 2252/4885 |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | CA4, FLT4, CAMK4 | CETP 498/4885 |
| US-20100331309-A1 | Trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GRIK5, NT5C | CETP 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.